Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alon Kahana

Ophthalmic Plastic and Reconstructive Surgery Livonia, MI Medical Doctor

NPI 1124094651 CMS profile 1107173

39000 7 Mile Rd Ste 2400, Livonia, MI 48152

Open in the dashboard

General payments

$181,149

178 records reported · program years 2019–2025

Research payments

$4,250

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$79,052 paid to institutions, not to them · program year 2019

Through program year 2025, Alon Kahana of Livonia, MI is reported in the CMS Open Payments database as having received $181,149 across 178 general payments and $4,250 in research payments paid to them. Separately, studies naming them as principal investigator received $79,052 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Ophthalmic Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,174 42
2024 General $21,173 43
2023 General $16,247 25
2022 General $20,392 26
2021 General $11,873 12
2020 General $3,481 6
2020 Research $4,250 1
2019 General $56,810 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alon Kahana
  • Ophthalmic Plastic and Reconstructive Surgery median
  • Middle half of Ophthalmic Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Alon Kahana were reported at $51,174. Among 325 Ophthalmic Plastic and Reconstructive Surgery profiles paid that year, the median was $298 and the middle half received between $132 and $820.

Show as a table
Year Alon Kahana Ophthalmic Plastic and Reconstructive Surgery median Middle half National median
2019 $56,810 $182 $73–$467 $163
2020 $3,481 $125 $41–$412 $114
2021 $11,873 $173 $52–$538 $132
2022 $20,392 $237 $78–$809 $149
2023 $16,247 $291 $103–$776 $160
2024 $21,173 $304 $108–$822 $164
2025 $51,174 $298 $132–$820 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TissueTech, Inc. $107,677 45 payments
  2. Genentech, Inc. $36,800 2 payments
  3. Horizon Therapeutics plc $26,528 51 payments
  4. Stryker Corporation $8,233 11 payments
  5. Amgen Inc. $898 35 payments
  6. ANI Pharmaceuticals, Inc. $316 15 payments
  7. Allergan Inc. $142 2 payments
  8. Mallinckrodt Hospital Products Inc. $113 4 payments
  9. AxoGen $104 1 payment
  10. Dompe US, Inc. $94 3 payments
  11. Other $244 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $161,258 35 payments
  2. Honoraria $6,860 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,600 2 payments
  4. Food and Beverage $4,516 129 payments
  5. Travel and Lodging $1,891 10 payments
  6. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. Non-Covered Product $32,505 1 payment
  2. PROKERA $7,072 10 payments
  3. AMNIOGRAFT $7,072 10 payments
  4. SONOPET IQ $4,950 3 payments
  5. Erivedge $4,375 2 payments
  6. TEPEZZA Tepezza $2,923 33 payments
  7. NSE - SONOPET $1,648 2 payments
  8. CORE $1,000 1 payment
  9. TEPEZZA Inflammation/Rare Disease $898 35 payments
  10. HOFFMANN $500 1 payment
  11. Other $2,024 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $4,250 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

170

Median for Ophthalmology: 891

Drug cost

$590,105

Median for Ophthalmology: $68,233

Branded share of claims

40%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxervate Cenegermin-Bkbj Brand 12 $557,145
Actemra Actpen Tocilizumab Brand 14 $30,395
Prednisolone Acetate Generic 29 $1,665
Erythromycin Erythromycin Base Brand 30 $439
Tranexamic Acid Generic 34 $276
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 12 $118
Azithromycin Generic 39 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$192,982

Medicare's payments for the services billed

Medicare patients

263

Average age 74

Services billed

1,123

177 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 46%
Diabetes 26%
Ischemic heart disease 26%
Depression 24%
Chronic kidney disease 22%
Osteoporosis 21%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
  • Amgen Inc. $429
$429 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $247
$247 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $51
$51 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmic Plastic and Reconstructive Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record